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Purpose of the Study
Efavirenz (EFV) is an important and frequently prescribed
component of triple-combination antiretroviral therapy.
However, many patients are unable to tolerate the neu-
ropsychiatric side-effects of this medication. Nevirapine
(NVP), another potent non-nucleoside RT inhibitor may
be able to be substituted for EFV in patients who experi-
ence side-effects. This study is a retrospective review of
patients in a large HIV specialty private practice who were
switched from EFV to NVP from 1998 through 2007. Ear-
lier results from a portion of this cohort have previously
been published [1].
Methods
Patients who were virologically controlled (HIV-1 PCR <
50) or initiating therapy on an EFV-based regimen were
switched to NVP, continuing the other components of
their regimen. EFV was continued during the 2-week
induction dosing of NVP; since 2003 for patients with T4
cell counts >400, NVP was started at 100 mg/day for 2
weeks then increased to 200 mg/day for another 2 weeks
before increasing to full dose.
Summary of Results
63 patients were identified who switched from EFV to
NVP. Patients had been on EFV from one to 69 months.
Mean T4 cell count at the time of switch was 607/mm3
(range 176–1236); 53 (84%) patients had a T4 count
greater than 400 at the time of switch. One patient had
acute hepatic toxicity at day 8 and is excluded from further
analyses. No patient developed a rash on initiation of
NVP. All patients became or have stayed undetectable
(HIV-1 PCR < 50) for periods from 6 to 116 months
(mean 50 months) after switch. The most recent T4 cell
count has increased by a mean 113 cells since switch (p <
0.001).
Lipid values (mean of last two values before switch com-
pared to mean of first two after switch) improved signifi-
cantly: total cholesterol decreased by 12 mg/dl (0.31
mmol/L) (p < 0.02), LDL decreased by 7 mg/dl (0.16
mmol/L) (p < 0.05), HDL increased by 6 mg/dl (0.18
mmol/L) (p < 0.001) and triglycerides decreased by 42
mg/dl (0.47 mmol/L) (p < 0.02).
Conclusion
NVP can be successfully substituted for EVF in patients
unable to tolerate the neuropsychiatric side-effects of EFV,
with maintenance of virologic control and improvement
of lipid parameters.
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